ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-16 10:14 |
Franchissement de seuil
|
French | 344.5 KB | ||
| 2025-09-16 10:09 |
Franchissement de seuil
|
French | 118.6 KB | ||
| 2025-09-16 09:59 |
Franchissement de seuil
|
French | 121.4 KB | ||
| 2025-09-12 17:45 |
Abivax intègrera les indices CAC Mid 60 et SBF 120 suite à la révision annuelle…
|
French | 160.0 KB | ||
| 2025-09-12 17:45 |
Abivax integrera les indices CAC Mid 60 et SBF 120 suite a la revision annuelle…
|
French | 21.0 KB | ||
| 2025-09-12 17:45 |
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual R…
|
English | 8.6 KB | ||
| 2025-09-08 22:00 |
Abivax présente ses résultats financiers du premier semestre 2025
|
French | 247.9 KB | ||
| 2025-09-08 22:00 |
Rapport CAC sur l'information semestrielle 2025
|
French | 5.8 MB | ||
| 2025-09-08 22:00 |
Lettre d'affirmation sur les comptes semestriels 2025
|
French | 413.6 KB | ||
| 2025-09-08 22:00 |
Rapport financier semestriel 2025
|
French | 5.7 MB | ||
| 2025-09-08 22:00 |
Déclaration de la personne responsable RFS - Abivax
|
French | 164.7 KB | ||
| 2025-09-08 22:00 |
Abivax Presents First Half 2025 Financial Results
|
English | 24.2 KB | ||
| 2025-09-08 14:28 |
Franchissement de seuil
|
French | 122.4 KB | ||
| 2025-09-08 14:25 |
Franchissement de seuils
|
French | 109.6 KB | ||
| 2025-09-02 10:55 |
Franchissement de seuil
|
French | 121.8 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
